{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Adaptimmune Therapeutics plc"},"Symbol":{"label":"Symbol","value":"ADAP"},"Address":{"label":"Address","value":"60 JUBILEE AVENUE MILTON PARK, ABINGDON, OX14 4RY, United Kingdom"},"Phone":{"label":"Phone","value":"+44 1235430000"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types."},"CompanyUrl":{"label":"Company Url","value":"https://www.adaptimmune.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Adrian Rawcliffe","title":"Chief Executive Officer &amp; Director"},{"name":"William C. Bertrand","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}